Challenges, solutions, and recommendations for Alzheimer's disease combination therapy

Area of Science:

• Neurology
• Pharmacology
• Biomedical Research

Background:

• Alzheimer's disease (AD) presents complex neuropathology necessitating combination therapy.
• Current treatment paradigms for AD are insufficient due to disease complexity.
• Significant scientific, regulatory, and business challenges impede the development of combination therapies for AD.

Purpose of the Study:

• To explore the challenges hindering combination therapy for Alzheimer's disease.
• To propose a strategic approach for facilitating proof-of-concept combination therapy trials in AD.
• To identify key areas for stakeholder collaboration in advancing AD combination treatments.

Main Methods:

• Expert consensus and strategic planning involving academia, industry, former FDA members, and the Alzheimer's Association.
• Analysis of scientific, pragmatic, regulatory, and business challenges in AD combination therapy.
• Development of a framework for future clinical trial designs and outcome assessments.

Main Results:

• A comprehensive strategy is proposed to overcome barriers to AD combination therapy.
• Emphasis on the need for an integrated understanding of AD pathophysiology and progression.
• Highlighting the necessity for novel clinical trial designs and appropriate outcome measures.

Conclusions:

• Collaboration among diverse stakeholders is crucial for advancing Alzheimer's disease combination therapy.
• A strategic, multi-faceted approach is required to facilitate proof-of-concept trials.
• Addressing the complex neuropathology of AD necessitates innovative therapeutic strategies.